ATE315394T1 - Benzothiazole als protein tyrosin-kinase inhibitoren - Google Patents

Benzothiazole als protein tyrosin-kinase inhibitoren

Info

Publication number
ATE315394T1
ATE315394T1 AT98957468T AT98957468T ATE315394T1 AT E315394 T1 ATE315394 T1 AT E315394T1 AT 98957468 T AT98957468 T AT 98957468T AT 98957468 T AT98957468 T AT 98957468T AT E315394 T1 ATE315394 T1 AT E315394T1
Authority
AT
Austria
Prior art keywords
benzothiazoles
tyrosine kinase
kinase inhibitors
protein tyrosine
protein
Prior art date
Application number
AT98957468T
Other languages
English (en)
Inventor
Jagabandhu Das
Joel C Barrish
John Wityak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE315394T1 publication Critical patent/ATE315394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98957468T 1997-11-10 1998-11-02 Benzothiazole als protein tyrosin-kinase inhibitoren ATE315394T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6504297P 1997-11-10 1997-11-10

Publications (1)

Publication Number Publication Date
ATE315394T1 true ATE315394T1 (de) 2006-02-15

Family

ID=22059964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957468T ATE315394T1 (de) 1997-11-10 1998-11-02 Benzothiazole als protein tyrosin-kinase inhibitoren

Country Status (25)

Country Link
US (1) US6825355B2 (de)
EP (1) EP1037632B1 (de)
JP (1) JP2001522800A (de)
KR (1) KR20010031912A (de)
CN (1) CN1290165A (de)
AR (1) AR017588A1 (de)
AT (1) ATE315394T1 (de)
AU (1) AU744281B2 (de)
BR (1) BR9814956A (de)
CA (1) CA2309319A1 (de)
DE (1) DE69833224T2 (de)
ES (1) ES2256969T3 (de)
HU (1) HUP0102101A3 (de)
ID (1) ID24289A (de)
IL (1) IL135176A0 (de)
NO (1) NO20002121L (de)
NZ (1) NZ503491A (de)
PE (1) PE129799A1 (de)
PL (1) PL340727A1 (de)
RU (1) RU2212407C2 (de)
TR (1) TR200001312T2 (de)
TW (1) TW510898B (de)
UY (1) UY25242A1 (de)
WO (1) WO1999024035A1 (de)
ZA (1) ZA9810219B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258686A1 (en) * 1998-05-29 2006-11-16 Cheresh David A Method of treatment of myocardial infarction
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
NZ513639A (en) * 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
ATE277044T1 (de) * 1999-10-06 2004-10-15 Boehringer Ingelheim Pharma Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB0003254D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
NZ522928A (en) 2000-06-21 2005-05-27 F Benzothiazole derivatives
MXPA03001306A (es) 2000-08-11 2003-10-15 Boehringer Ingelheim Pharma Compuestos heterociclicos utiles como inhibidores de las quinasas de tirosina.
AU2002232439A1 (en) * 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
BR0214019A (pt) * 2001-11-09 2004-10-13 Boehringer Ingelheim Phamaceut Benzimidazóis úteis como inibidores de proteìna quinase
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
EP1529046A1 (de) 2002-08-08 2005-05-11 Boehringer Ingelheim Pharmaceuticals Inc. Substituierte benzimidazolverbindungen
AU2003255767A1 (en) * 2002-08-10 2004-02-25 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
EP2426122A1 (de) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylenharnstoffderivate als Inhibitoren von RAF Kinase
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
CA2516234A1 (en) * 2003-02-21 2004-09-02 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
JP5229853B2 (ja) * 2003-02-28 2013-07-03 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な新規な二環尿素誘導体
WO2004085433A2 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
CA2528785A1 (en) * 2003-06-20 2005-01-06 Matthias Heinrich Nettekoven 2-amidobenzothiazoles as cb1 receptor inverse agonists
FR2864539B1 (fr) 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
DE102004006808A1 (de) * 2004-02-11 2005-09-01 Grünenthal GmbH Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
CN1956983B (zh) 2004-05-24 2010-05-26 弗·哈夫曼-拉罗切有限公司 4-羟基-4-甲基-哌啶-1-甲酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
CA2586931C (en) 2004-11-05 2013-08-06 Paul Spurr Process for preparation of isonicotinic acid derivatives
SE0403117D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
AU2006206611A1 (en) * 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-N- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as P2Y1 receptor inhibitors for the treatment of thromboembolic disorders
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
RU2412943C2 (ru) 2005-03-23 2011-02-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
WO2007002635A2 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7728008B2 (en) * 2005-06-27 2010-06-01 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006020871D1 (de) 2005-06-27 2011-05-05 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
US7714002B2 (en) * 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2009500378A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008109459A1 (en) * 2007-03-02 2008-09-12 University Of Massachusetts Luciferins
JP2008222084A (ja) * 2007-03-14 2008-09-25 Yamaha Motor Electronics Co Ltd 電動ゴルフカーのブレーキ劣化検出方法及びこれを用いた電動ゴルフカー
WO2008124393A1 (en) * 2007-04-04 2008-10-16 Irm Llc Benzothiazole derivatives and their use as protein kinase inhibitors
FR2928547B1 (fr) 2008-03-13 2012-03-09 Lvmh Rech Extrait de l'orchidee brassocattle marcella koss et son utilisation en tant qu'actif de depigmentation cutanee
CA2757415C (en) 2009-04-02 2018-02-06 Merck Patent Gmbh Autotaxin inhibitors
EP2424533A4 (de) 2009-04-27 2012-10-17 High Point Pharmaceuticals Llc Substituierte isochinolinderivate, pharmazeutische zusammensetzungen damit und verfahren zu ihrer verwendung als beta-sekretase-hemmer
CN101701018B (zh) * 2009-11-05 2012-06-13 东南大学 2-(4-氨基喹唑啉基)苯并[d]噻唑类衍生物及其用途
EP2549874A4 (de) * 2010-03-23 2013-10-02 High Point Pharmaceuticals Llc Substituierte imidazo[1,2-b]pyridazinderivate, pharmazeutische zusammensetzungen und verfahren zur verwendung als beta-sekretase-hemmer
HUE037860T2 (hu) 2010-11-19 2018-09-28 Ligand Pharm Inc Heterociklusos aminok és alkalmazásuk
MY167575A (en) * 2011-10-14 2018-09-20 Ambit Biosciences Corp Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
WO2014031441A1 (en) * 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
CN103058954A (zh) * 2013-01-07 2013-04-24 盛世泰科生物医药技术(苏州)有限公司 一种[6-(5-氨基-2-甲基-苯氨基甲酰-苯并噻唑]-氨基甲酸叔丁酯的制备方法
KR101804650B1 (ko) * 2013-03-20 2018-01-10 에프. 호프만-라 로슈 아게 우레아 유도체 및 이의 지방산 결합 단백질(fabp) 억제제로서의 용도
WO2014168262A1 (en) * 2013-04-11 2014-10-16 D.D.P. Corporation Kinase inhibitors containing cyclopropane skeleton
EP2990027A1 (de) 2014-09-01 2016-03-02 Institut Curie Peptidische Hautbleichungsagenzien
JP6690543B2 (ja) * 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
MX374526B (es) 2015-06-22 2025-03-06 Actelion Pharmaceuticals Ltd Inhibidores de nadph oxidasa 4.
KR102089122B1 (ko) * 2016-08-25 2020-03-13 주식회사 엘지화학 디아민 화합물 및 이를 이용하여 제조된 플렉시블 소자용 기판
CN107021937B (zh) * 2017-03-27 2019-06-21 沈阳药科大学 苯并噻唑甲酰胺类化合物及其应用
CN108794487B (zh) * 2017-05-04 2020-11-10 上海长森药业有限公司 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
CA3067070A1 (en) * 2017-06-14 2018-12-20 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
ES2953025T3 (es) * 2017-10-02 2023-11-07 1St Biotherapeutics Inc Compuestos de benzotiazol y métodos que usan los mismos para tratar trastornos neurodegenerativos
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CN115594671B (zh) * 2021-07-08 2024-03-15 沈阳药科大学 苯并噻唑类衍生物及其制备方法和用途
CN117751940B (zh) * 2023-11-09 2025-08-12 贵州道元生物技术有限公司 一种复合杀菌剂和制备工艺

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966706A (en) * 1971-01-27 1976-06-29 Ciba-Geigy Ag 2,6-Dihydroxy-3-cyano-4-methylpyridine containing azo dyes which contain a functional amino group
JPS50140442A (de) * 1974-04-16 1975-11-11
JPS5632549A (en) * 1979-08-27 1981-04-02 Toyo Ink Mfg Co Ltd Pigment composition
JPS62194251A (ja) * 1986-02-20 1987-08-26 Konishiroku Photo Ind Co Ltd 保存安定性が改良されたハロゲン化銀写真感光材料
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
US4970318A (en) * 1988-05-24 1990-11-13 Pfizer Inc. Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) * 1989-05-11 1994-08-31 東洋紡績株式会社 新規なベンゾチアゾール誘導体
JP2869561B2 (ja) 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
ZW1992A1 (en) * 1991-02-25 1993-09-22 Janssen Pharmaceutica Nv 4-/(2-benzotiazolyl)methylamino/-b-/(3,4-difluorephenoxy)methyl/-1-piperidine ethanol
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
WO1994019336A1 (fr) * 1993-02-19 1994-09-01 Asahi Kasei Kogyo Kabushiki Kaisha Derive de benzothiazolesulfonamide, procede de production et application de ce derive
US5496816A (en) 1994-03-14 1996-03-05 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
JP4274584B2 (ja) 1996-12-06 2009-06-10 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビター
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives

Also Published As

Publication number Publication date
WO1999024035A1 (en) 1999-05-20
ES2256969T3 (es) 2006-07-16
AR017588A1 (es) 2001-09-12
IL135176A0 (en) 2001-05-20
CA2309319A1 (en) 1999-05-20
KR20010031912A (ko) 2001-04-16
PL340727A1 (en) 2001-02-26
CN1290165A (zh) 2001-04-04
ID24289A (id) 2000-07-13
US20020123484A1 (en) 2002-09-05
TR200001312T2 (tr) 2000-09-21
US6825355B2 (en) 2004-11-30
AU1371999A (en) 1999-05-31
PE129799A1 (es) 2000-03-08
RU2212407C2 (ru) 2003-09-20
JP2001522800A (ja) 2001-11-20
NO20002121D0 (no) 2000-04-26
DE69833224D1 (en) 2006-04-06
EP1037632A1 (de) 2000-09-27
EP1037632A4 (de) 2002-08-21
HUP0102101A3 (en) 2002-11-28
EP1037632B1 (de) 2006-01-11
DE69833224T2 (de) 2006-09-28
NZ503491A (en) 2002-08-28
HUP0102101A2 (hu) 2001-11-28
ZA9810219B (en) 2000-06-22
TW510898B (en) 2002-11-21
UY25242A1 (es) 2001-08-27
AU744281B2 (en) 2002-02-21
BR9814956A (pt) 2000-10-03
NO20002121L (no) 2000-05-09

Similar Documents

Publication Publication Date Title
ATE430149T1 (de) Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
ATE255575T1 (de) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
CY2014034I1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
ATE214381T1 (de) Thiazole derivate als protein kinase c inhibitoren
NO20014970D0 (no) Cyklisk protein-tyrosin-kinase-inhibitor
CY2008015I1 (el) Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
ID29028A (id) Pirolopirimidina sebagai penghambat protein kinase
ATE172199T1 (de) Proteinkinase-c-inhibitor
ATE546139T1 (de) Isoprentransferase proteine inhibitoren
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
NO20021820D0 (no) Tyrosinkinaseinhibitorer
EP1161433A4 (de) Tyrosin-kinase-inhibitoren
NO20023713D0 (no) 2-benzotiazolyl-urea-derivater samt anvendelse derav som proteinkinaseinhibitorer
DE59803108D1 (de) 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
NO20002990L (no) Nytt overflateprotein
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
DE69938258D1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
HK1028329A (en) Benzothiazole protein tyrosine kinase inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1037632

Country of ref document: EP

REN Ceased due to non-payment of the annual fee